The efficacy of sodium glucose co-transport-2 inhibitors on glycemic control for patients with type 1 diabetes mellitus: A protocol for systematic review and meta-analysis. Issue 27 (9th July 2021)

• Record Type: Journal Article
• Authors: Zhang, Yajie; Gan, Ping; Huo, Yanan
• Is Part Of: Medicine. Volume 100:Issue 27(2021)
• Page Start: e26417
• Publication Date: 2021-07-09
• Subjects: meta-analysis -- protocol -- SGLT2 inhibitors -- type 1 diabetes mellitus; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000026417
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Currently, there are a number of sodium glucose co-transport-2 (SGLT2) inhibitors that are under development or in clinical trials. Prior meta-analyses had established the safety and efficacy of SGLT2 inhibitors in type 1 diabetes mellitus (T1DM), but with low level of evidences and inconsistent conclusions. However, recently many new randomized clinical trials (RCTs) have been published, we hence try to design a study protocol to assess the effect of SGLT2 inhibitors on cardiovascular events via a comprehensive meta-analysis of data from much more RCTs, including sensitivity and subgroup analyses. Methods: We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines to conduct this meta-analysis. Two investigators will perform a systematic search of scientific literature in the databases (from conception through June 12, 2021), including PubMed, Embase, and Cochrane Central Register of Controlled Trials. This meta-analysis will be conducted using RevMan statistical software. The risk of bias for each included study will be assessed using the Cochrane Risk of Bias Assessment Tool. Results: Our protocol is conceived to test the hypothesis that SGLT2 inhibitors could lead to better outcomes in patients presenting with T1DM. Registration number: 10.17605/OSF.IO/ZD8WX.